Mizuho Begins Coverage on Pulse Biosciences (NASDAQ:PLSE)

Equities research analysts at Mizuho started coverage on shares of Pulse Biosciences (NASDAQ:PLSE) in a research note issued on Friday, Marketbeat.com reports. The firm set an “outperform” rating and a $25.00 price target on the stock. Mizuho’s price objective indicates a potential upside of 83.55% from the company’s previous close.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pulse Biosciences in a research note on Thursday, January 22nd. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $23.50.

Pulse Biosciences Stock Up 0.5%

NASDAQ PLSE opened at $13.62 on Friday. Pulse Biosciences has a fifty-two week low of $12.56 and a fifty-two week high of $25.00. The business has a fifty day moving average of $14.08 and a 200-day moving average of $15.47. The stock has a market cap of $923.00 million, a price-to-earnings ratio of -12.05 and a beta of 1.69.

Pulse Biosciences (NASDAQ:PLSE) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.29) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.02.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Sanctuary Advisors LLC acquired a new position in shares of Pulse Biosciences in the fourth quarter valued at $244,000. Argo Wealth Advisory LLC acquired a new stake in Pulse Biosciences in the 4th quarter valued at $387,000. Farther Finance Advisors LLC boosted its stake in shares of Pulse Biosciences by 39.2% in the 4th quarter. Farther Finance Advisors LLC now owns 20,373 shares of the company’s stock valued at $280,000 after purchasing an additional 5,734 shares in the last quarter. Westside Investment Management Inc. increased its position in shares of Pulse Biosciences by 2.9% during the 4th quarter. Westside Investment Management Inc. now owns 66,326 shares of the company’s stock worth $911,000 after purchasing an additional 1,886 shares in the last quarter. Finally, Quotient Wealth Partners LLC bought a new position in Pulse Biosciences during the 4th quarter valued at about $218,000. 76.95% of the stock is owned by institutional investors.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.